Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Neuroendocrine Tumours Treatment Recommendations

eUpdate – Neuroendocrine Tumours Treatment Recommendations

Published: 20 September 2016. Authors: ESMO Guidelines Committee

Clinical Practice Guidelines

This update refers to the Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Öberg K, Hellman P, Ferolla P and Papotti A, Ann Oncol 2012; 23 (Suppl 7): vii120-vii123; and the Neuroendocrine gastro-entero-pancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Öberg K, Knigge U, Kwekkeboom D and Perren A, Ann Oncol 2012; 23 (Suppl 7): vii124-vii130.

Section

Management of advanced/metastatic disease

Text update

In the randomised, double-blind, placebo-controlled, phase III RADIANT-4 trial, 302 patients with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were randomised in a 2:1 ratio to everolimus 10 mg per day orally or placebo, both with supportive care. The primary endpoint was progression-free survival (PFS), while overall survival (OS) and quality of life were secondary endpoints. Median PFS was 11.0 months (95% CI 9.2–13.3) in the everolimus group and 3·9 months (3.6–7.4) in the placebo group (hazard ratio [HR] 0.48 [95% CI 0.35–0.67], p<0·00001). Although not statistically significant, the results of the first pre-planned interim OS analysis indicated that everolimus might be associated with a reduction in the risk of death (HR 0.64 [95% CI 0.40–1.05], one-sided p=0.037). Grade 3 or 4 drug-related adverse events were infrequent and manageable, though more numerous in the everolimus group.

Recommendation

In patients with unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin with progressive disease, everolimus, as compared with placebo, is associated with a statistically and clinically significant improvement in PFS.In the absence of mature OS and quality of life data, the observed PFS benefit is associated with an ESMO Magnitude of Clinical Benefit Scale (MCBS) score of 3.

Magnitude of Clinical Benefit Scale (MCBS) table for new therapies/indications in neuroendocrine tumours (bronchial, thymic and gastro-entero-pancreatic)a

Therapy

Everolimus in unresectable or metastatic disease

Disease setting

Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease

Trial

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study [1]

NCT01524783

Phase

III

Control

Placebo

Median PFS: 3.9 months

Absolute survival gain

PFS gain: 7.1 months

OS benefit, not statistically significant yet

HR (95% CI)

PFS HR: 0.48 (0.35-0.67)

QoL/toxicity

Deteriorated toxicity profile

QoL was a secondary endpoint, however no data are available yet

ESMO-MCBS scoreb

3 (Form 2b; mature data on OS not available, data on QoL assessment not available)

aEMA approvals in 2016 to end August 2016.
bESMO-MCBS version 1.0 [2]
HR, hazard ratio; CI, confidence interval; QoL, quality of life; mTOR, mammalian target of rapamycin; PFS, progression-free survival; OS, overall survival, EMA, European Medicines Agency

References

  1. Yao JC, Fazio N, Singh S et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968–977.
  2. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547–1573.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings